FILT and Aerocrine will collaborate to develop new applications for airway inflammation monitoring and FILT will cease further commercialization of the NO VARIO product.

Aerocrine CEO Paul de Potocki said the technology platform and intellectual property acquired from FILT may prove valuable for their continued endeavors to further develop products to measure airway inflammation.

FILT GM Rudiger Eichler said it requires significant resources to develop the technology and the international clinical documentation for products used in a major therapeutic area such as asthma.